BioSpace News Archive

Expansion Therapeutics, Inc. today announced the appointment of Sudhir Rao, M.S., M.B.A., to the position of Senior Vice President of Business Development.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced the publication of positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.

Revelation Biosciences Inc. announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 1,293,126 shares of Common Stock.

The Monell Chemical Senses Center announced today it has received a grant of up to $26 million from its founding benefactor, The Ambrose Monell Foundation.

Virica Biotech Inc. today announced it will collaborate with Oxford Biomedica plc to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers ( VSEs™ ).

Peptilogics, a biotech company that designs peptide therapeutics, today announced that it has promoted Nicholas Nystrom, Ph.D., formerly SVP and Head of Computation and Data, to Chief Technology Officer.

Waters Corporation announced the U.S. Food and Drug Administration’s Office of Regulatory Affairs has purchased Waters™ Empower™ Chromatography Data Software and NuGenesis™ Laboratory Management Software, expanding its deployment of Waters’ software to support its medical products testing operations across its five field science laboratories.

Arcturus Therapeutics Holdings Inc. today announced updated data from clinical development programs for ARCT-154 and ARCT-165.

AnHeart Therapeutics Appoints Prof. Andrés Cervantes to Scientific Advisory Board.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease theragnostic joint venture partner NLC Pharma Ltd., today announced a data lock for the interim data analysis for the Company’s Tollovir™ Phase 2 Clinical Trial for the treatment of hospitalized (severe/critical) COVID-19 patients.